Generex To Aqurie Controlling Share In Israeli Biotech Firm

October 14, 2015 | Israeli bio-medical company Meditemp has signed a non-binding Letter of Intent with Generex Biotechnology, which according to the letter, could acquire a 51% equity interest in MediTemp in exchange for a purchase price of $5 million. Founded in 2007, MediTemp has developed a proprietary cooling technology designed to improve sperm quality in men rendered infertile due to varicoceles, a condition characterized by enlarged veins (varicose) within the scrotum. The company’s solution is called Varicure, a wearable, compact, portable and comfortable device that facilitates localized cooling of the testicles with the aim of enhancing male fertility by improving sperm quality.